000142446 001__ 142446
000142446 005__ 20240229105148.0
000142446 0247_ $$2doi$$a10.18632/oncotarget.25439
000142446 0247_ $$2pmid$$apmid:29899854
000142446 0247_ $$2pmc$$apmc:PMC5995230
000142446 0247_ $$2altmetric$$aaltmetric:43749657
000142446 037__ $$aDKFZ-2019-00166
000142446 041__ $$aeng
000142446 082__ $$a610
000142446 1001_ $$aKähler, Katharina C$$b0
000142446 245__ $$aThe outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians.
000142446 260__ $$a[S.l.]$$bImpact Journals LLC$$c2018
000142446 3367_ $$2DRIVER$$aarticle
000142446 3367_ $$2DataCite$$aOutput Types/Journal article
000142446 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1549873910_1500
000142446 3367_ $$2BibTeX$$aARTICLE
000142446 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142446 3367_ $$00$$2EndNote$$aJournal Article
000142446 520__ $$aAfter more than two decades with interferon alfa-2a and 2b (IFN) as the only approved drugs in the adjuvant setting for melanoma, new treatment approaches like immune checkpoint inhibitors and BRAF-MEK inhibitors improve the progression free survival (PFS) and also the overall survival (OS). We compared physicians' preferences ('utilities') for health states associated with IFN therapy to their patients' preferences. Utilities describe a preference for a specific health state on a scale of 0 (as bad as death) to 1.0 (perfect health).We assessed utilities for health states associated with adjuvant IFN using the standard gamble technique in 108 physicians and 130 melanoma patients. Four IFN toxicity scenarios and three outcome scenarios were given to the participants. Both groups were asked for the 5-year disease free survival (DFS) they would need to accept the described IFN-related side effects.In both groups, utilities for melanoma relapse were significantly lower than for IFN side effects, showing that toxicity was more acceptable than relapse. Physicians indicated higher utilities for each scenario and needed lower 5-year DFS both in case of mild-to-moderate and severe side effects. Patients were willing to tolerate mild-to-moderate and severe toxicity for a 50% and 75% chance of 5-year DFS, while physicians only required a chance of 40% and 50%, respectively.Both physicians and patients rated melanoma recurrence much lower than even severe IFN side effects. In direct comparison, physicians rated cancer-related scenarios more positively and accepted IFN toxicity for an even lower treatment benefit.
000142446 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142446 588__ $$aDataset connected to CrossRef, PubMed,
000142446 7001_ $$aBlome, Christine$$b1
000142446 7001_ $$aForschner, Andrea$$b2
000142446 7001_ $$aGutzmer, Ralf$$b3
000142446 7001_ $$aHauschild, Axel$$b4
000142446 7001_ $$aHeinzerling, Lucie$$b5
000142446 7001_ $$aLivingstone, Elisabeth$$b6
000142446 7001_ $$aLoquai, Carmen$$b7
000142446 7001_ $$aMüller-Brenne, Tina$$b8
000142446 7001_ $$aSchadendorf, Dirk$$b9
000142446 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b10$$udkfz
000142446 7001_ $$aWagner, Tobias$$b11
000142446 7001_ $$aAugustin, Matthias$$b12
000142446 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.25439$$gVol. 9, no. 40$$n40$$p2621-26225$$tOncoTarget$$v9$$x1949-2553$$y2018
000142446 909CO $$ooai:inrepo02.dkfz.de:142446$$pVDB
000142446 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142446 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142446 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142446 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142446 9141_ $$y2018
000142446 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000142446 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142446 9201_ $$0I:(DE-He78)G300-20160331$$kG300$$lKKE Dermatoonkologie$$x0
000142446 980__ $$ajournal
000142446 980__ $$aVDB
000142446 980__ $$aI:(DE-He78)G300-20160331
000142446 980__ $$aUNRESTRICTED